
Cytokinetics announced FDA approval to update MYQORZO's prescribing information to include Phase 3 MAPLE-HCM trial data comparing MYQORZO (aficamten) to the beta-blocker metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO showed significantly better improvements in exercise capacity, symptoms, and cardiac biomarkers than metoprolol. This makes MYQORZO the only cardiac myosin inhibitor with direct comparative data to beta-blockers in its U.S. label, aiding treatment decisions. MYQORZO carries a heart failure risk warning and is available only through a restricted REMS program due to potential systolic dysfunction.
Cytokinetics Inc (CYTK) has a market capitalization of $7.81 billion and an enterprise value of $7.95 billion as of November 16, 2026, 16:11 WIB. The stock price on Pluang is USD 56.00, down slightly by 0.23% on the day, with a trading volume of 1,013,535 shares. The typical hold time for CYTK on Pluang is 21 days, indicating moderate investor interest in the health sector stock amid recent FDA updates.